LGVN LGVN
Company Profile ↓Company Overview
LGVN (LGVN) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $1.20M (-49.9% YoY); net profit $-22.70M.
- Trailing 12 Months Year-on-year growth — revenue -49.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -26.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -26.60% |
| 1 Year: | -49.87% |
Stock Price Performance
| 1 Year: | -57.48% |
| 6 Months: | +31.48% |
| 3 Months: | -15.06% |
| 1 Month: | +15.05% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)59.54 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -26.6% CAGR over 5 years.
- Trading 57.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 217.00K | 150.00K | 548.00K | 468.00K | 773.00K | 381.00K | 316.00K | 137.00K | 398.00K |
| Gross Profit | 812.00K | 112.00K | 373.00K | 149.00K | 208.00K | 164.00K | 165.00K | 160.00K | 92.00K | 76.00K | 93.00K | 54.00K | 329.00K | 344.00K | 682.00K | 275.00K | 146.00K | 125.00K | 264.00K |
| Operating Income | -213.00K | -1.23M | -958.00K | -3.46M | -5.06M | -4.91M | -3.39M | -4.22M | -5.19M | -4.72M | -5.71M | -5.16M | -4.09M | -3.50M | -4.65M | -5.18M | -5.40M | -7.31M | -4.78M |
| Net Income | -213.00K | -1.22M | - | -3.11M | -5.01M | -4.86M | -3.51M | -5.62M | -5.24M | -4.65M | -5.63M | -5.11M | -4.06M | -3.41M | -4.42M | -5.01M | -5.03M | -7.22M | -4.74M |
| Diluted EPS | - | - | - | - | -0.26 | -0.25 | -0.17 | -0.27 | -0.25 | -2.21 | -2.67 | -2.79 | -1.61 | -1.83 | -0.34 | -0.34 | -0.33 | -0.39 | -0.19 |
| R&D Expense | 289.00K | 642.00K | 585.00K | 1.35M | 1.96M | 2.05M | 1.29M | 1.72M | 2.96M | 2.78M | 2.29M | 1.84M | 2.22M | 1.72M | 2.21M | 2.52M | 2.95M | 3.85M | 2.32M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 5.63M | 1.31M | 1.22M | 709.00K | 2.39M | 1.20M |
| Gross Profit | 1.83M | 590.00K | 497.00K | 221.00K | 1.88M | 803.00K |
| Operating Income | -3.78M | -17.46M | -18.04M | -21.03M | -16.52M | -23.29M |
| Net Income | -3.72M | -17.05M | -18.84M | -21.41M | -15.97M | -22.70M |
| Diluted EPS | - | -0.90 | -0.90 | -10.22 | -2.62 | -1.29 |
| R&D Expense | 2.67M | 7.09M | 9.37M | 9.07M | 8.14M | 12.04M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 9.24M | 42.77M | 27.41M | 12.08M | 25.56M | 10.26M |
| Total Equity | 4.45K | 1.96M | 37.45M | 20.50M | 6.74M | 21.89M | 5.67M |
| Cash & Equivalents | - | 816.00K | 25.66M | 10.50M | 4.95M | 19.23M | 4.66M |
| Long Term Debt | - | 311.00K | - | - | - | - | - |
| Total Liabilities | - | 7.28M | 5.31M | 6.91M | 5.34M | 3.67M | 4.59M |
| Current Liabilities | - | 3.83M | 2.71M | 4.87M | 3.89M | 2.58M | 4.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.36M | -9.64M | -13.97M | -19.00M | -13.87M | -18.64M |
| Investing Cash Flow | -261.00K | -10.70M | -677.00K | 8.19M | -640.00K | -595.00K |
| Financing Cash Flow | 1.57M | 45.17M | -509.00K | 5.26M | 28.79M | 4.67M |
| Capital Expenditure | -131.00K | -330.00K | -569.00K | -301.00K | -655.00K | -245.00K |
| Free Cash Flow | -2.50M | -9.97M | -14.54M | -19.30M | -14.52M | -18.89M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 32.4% | 45.2% | 40.7% | 31.2% | 78.8% | 67.0% |
| Operating Margin % | -67.1% | -1,336.6% | -1,476.5% | -2,966.0% | -690.7% | -1,942.2% |
| Net Margin % | -66.1% | -1,305.1% | -1,541.3% | -3,020.2% | -667.8% | -1,893.6% |
| ROE % | -190.1% | -45.5% | -91.9% | -317.7% | -73.0% | -400.1% |
| ROCE % | -69.8% | -43.6% | -80.0% | -256.8% | -71.9% | -377.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LGVN
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today annou…
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
Dr. Ascheim has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologics Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Long…
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “Laromestrocel Stabilizes Brain I…
Longeveron® Appoints Marie Washburn as Chief Financial Officer
Marie Washburn Marie Washburn, Longeveron CFO Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectorsCorporate focus on delivering top-line results from the Phase 2b clinical trial evaluati…
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that addi…
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the …
LGVN — Frequently Asked Questions
What is the current share price of LGVN?
As of 2026-08-05 17:25 PDT, LGVN trades at $0.73 on NASDAQ/NYSE. Its 52-week range is $0.48 to $1.71.
What is the P/E ratio of LGVN?
LGVN trades at a trailing price-to-earnings (P/E) ratio of -0.57.
Is LGVN a good stock to buy?
This page provides a data-driven analysis of LGVN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.